title: VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets.
abstract: The concept that tumors can be controlled by directly targeting their vascular supply has finally come of age, because clinical trials using a humanized monoclonal antibody that blocks VEGF have demonstrated exciting efficacy in cancer patients, as well as in vascular eye diseases that can lead to blindness. However, data suggest that these current regimens may not provide complete VEGF inhibition and, thus, that the maximum therapeutic potential of VEGF blockade has not yet been achieved. We describe the status of a very potent and high-affinity VEGF blocker, termed the VEGF Trap, that may provide the opportunity to maximize the potential of VEGF blockade in cancer as well as in vascular eye diseases. We also describe use of the VEGF Trap as a research tool, when coupled to high-throughput mouse genetics approaches such as VelociGene that can be exploited in strategies to discover and validate the next generation of angiogenesis targets.
authors.affiliation: Regneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Rudge
authors.forename: G
authors.initials: G
authors.lastname: Thurston
authors.forename: S
authors.initials: S
authors.lastname: Davis
authors.forename: N
authors.initials: N
authors.lastname: Papadopoulos
authors.forename: N
authors.initials: N
authors.lastname: Gale
authors.forename: S J
authors.initials: SJ
authors.lastname: Wiegand
authors.forename: G D
authors.initials: GD
authors.lastname: Yancopoulos
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D042682:Angiopoietins / Q000037:antagonists & inhibitors; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005128:Eye Diseases / Q000628:therapy*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D051379:Mice; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000628:therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000235:genetics / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D042682:Angiopoietins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D042461:Vascular Endothelial Growth Factor A; C064045:delta protein; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor